Real-World Data Analysis of CDK4/6 Inhibitor Therapy—A Patient-Centric Single Center Study
I Ge, K Berner, M Mathis, C Hensgen, S Mayer, T Erbes… - Cancers, 2024 - mdpi.com
Simple Summary In this study, we investigated the effectiveness of the targeted cancer
medication CDK4/6 inhibitors, in patients with breast cancer. These medicaments have been …
medication CDK4/6 inhibitors, in patients with breast cancer. These medicaments have been …
Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer–a nationwide, retrospective study
Background and purpose Capecitabine can be used as first-line treatment for advanced
breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse …
breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse …
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis
M Püsküllüoğlu, M Pieniążek, A Rudzińska… - Oncology and …, 2024 - Springer
Methods In this retrospective single-center cohort study data of patients treated with cisplatin
monotherapy (60–80 mg/m 2, every 3–4 weeks) between 2016 and 2023 at a reference …
monotherapy (60–80 mg/m 2, every 3–4 weeks) between 2016 and 2023 at a reference …
First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report
EA Pangarsa, PD Astuti, D Rizky, K Tandarto… - Journal of Medical Case …, 2024 - Springer
Metastatic breast cancer especially in disseminated carcinomatosis of bone marrow (DCBM)
poses a life-threatening risk, often requiring systemic chemotherapy. This situation lacks a …
poses a life-threatening risk, often requiring systemic chemotherapy. This situation lacks a …
Das metastasierte Mammakarzinom–ein Überblick zur Entwicklung der Therapiestandards 2024
C Thomssen, TW Park-Simon - Die Gynäkologie, 2024 - Springer
Zusammenfassung Die Diagnose der Metastasierung eines Mammakarzinoms ist für die
betroffene Patientin eine erschreckende Nachricht; der Begriff ist mit der vitalen Bedrohung …
betroffene Patientin eine erschreckende Nachricht; der Begriff ist mit der vitalen Bedrohung …
[HTML][HTML] Delta Hemoglobin-Albümin-Lenfosit-Trombosit (HALP) Skoru Metastatik Meme Kanserinde CDK4/6 İnhitibitörü ile Erken Progresyon Riskini Predikte Eder mi?
BB GÜLBAĞCI, Ö Miraç, EÖ ENGİN… - 2024 - namikkemalmedj.com
Bu retrospektif çalışmaya, 1 Ocak 2020 ile 30 Eylül 2023 tarihleri arasında Sakarya
Üniversitesi Eğitim ve Araştırma Hastanesi'nde CDK4/6 inhibitörü endokrin tedavi alan …
Üniversitesi Eğitim ve Araştırma Hastanesi'nde CDK4/6 inhibitörü endokrin tedavi alan …
[HTML][HTML] Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors?
BB GÜLBAĞCI, Ö Miraç, EÖ ENGİN… - 2024 - namikkemalmedj.com
Aim This study aims to determine the predictive value of dynamic change in hemoglobin-
albumin-lymphocyte-platelet (HALP) score on treatment response in hormone-positive …
albumin-lymphocyte-platelet (HALP) score on treatment response in hormone-positive …
Definition of Visceral Crisis in Hormone Receptor-Positive Her2-Negative Advanced Breast Cancer: Delphi Consensus Among Experts from the Unicancer French …
R NABETH, M Barthoulot, PH Cottu, JY Pierga… - papers.ssrn.com
Therapeutic management of patients with luminal advanced breast cancer (ABC) has been
revolutionized by the combination of CDK4/6 inhibitors with endocrine therapy, now the gold …
revolutionized by the combination of CDK4/6 inhibitors with endocrine therapy, now the gold …